The U.S. Food and Drug Administration has approved Elura (capromorelin oral solution) as the first drug for the management of weight loss in cats with chronic kidney disease.
Chronic kidney disease, also known as CKD, is the persistent loss of kidney function over time. Cats with chronic kidney disease may begin to lose weight before getting diagnosed by a veterinarian and typically continue to lose weight as the disease progresses.
Capromorelin, the active ingredient in Elura, provides a novel mechanism of action to address weight loss in cats with CKD. It stimulates appetite and the secretion of growth hormone. Weight gain in cats taking Elura is thought to be due to a combination of increased food intake and metabolic changes.
Capromorelin is also approved as Entyce for appetite stimulation in dogs. Elura is the second product that the FDA has approved for the management of unintended weight loss in cats. The first product, Mirataz, is an appetite stimulant applied topically to the skin. Learn more about the approval of Elura.
Signs of Weight Loss in Cats
It is important to keep an eye on your cat’s eating habits and observe any changes in their body condition while holding or petting them. Report these changes to your veterinarian.
- Reduced interest in food
- Changes in the amount eaten
- An increased amount of time taken to eat
- Bony protrusions or ribs
- Tender spots
- Lumps or bumps
If you are concerned about your cat’s weight loss, speak with your veterinarian about treatment options.
This information is not intended to diagnose or treat any disease and is purely educational. Please seek advice from your pet’s veterinarian with any questions regarding the health of your pet.